InMed Pharmaceuticals Inc. (INM)
NASDAQ·Healthcare·Biotechnology
$0.72
-1.72%
Mkt Cap $1.54M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 11, 2026 | — | $1.13M | — | — | -$0.51 | — | — | — |
| Q4 2025 Nov 6, 2025 | — | $1.12M | — | — | -$0.44 | — | — | — |
| Q3 2025 Sep 23, 2025 | — | $1.78M | — | — | -$3.80 | — | — | — |
| Q2 2025 May 12, 2025 | — | $1.80M | — | — | -$1.94 | — | — | — |
| Q1 2025 Feb 12, 2025 | — | $772.53M | — | — | -$3.64 | — | — | — |
| Q4 2024 Nov 14, 2024 | — | $936.16K | — | — | -$54.20 | — | — | — |
| Q3 2024 Sep 27, 2024 | $1.79M | $938.46K | -47.57% | — | -$3.80 | — | — | — |
| Q2 2024 May 14, 2024 | $1.79M | $863.50K | -51.76% | — | -$3.60 | — | — | — |
| Q1 2024 Feb 13, 2024 | $1.13M | $933.78K | -17.36% | — | -$3.80 | — | — | — |
| Q4 2023 Nov 14, 2023 | $1.39M | $1.25M | -10.07% | — | -$15.20 | — | — | — |
| Q3 2023 Sep 29, 2023 | $321.00K | $1.74M | +443.49% | -$85.00 | -$12.92 | +84.80% | — | — |
| Q2 2023 May 15, 2023 | $321.00K | $764.09K | +138.03% | -$90.00 | -$12.00 | +86.67% | — | — |
| Q1 2023 Feb 17, 2023 | $500.00K | $350.12K | -29.98% | -$90.00 | -$18.20 | +79.78% | — | — |
| Q4 2022 Nov 11, 2022 | $500.00K | $234.25K | -53.15% | -$85.00 | -$81.20 | +4.47% | — | — |
| Q3 2022 Sep 23, 2022 | $750.00K | $399.63K | -46.72% | -$110.00 | -$258.40 | -134.91% | — | — |
| Q2 2022 May 13, 2022 | $309.58K | $247.63K | -20.01% | -$115.00 | -$125.00 | -8.70% | — | — |
| Q1 2022 Feb 14, 2022 | $125.00K | $207.89K | +66.31% | -$120.00 | -$155.00 | -29.17% | — | — |
| Q4 2021 Nov 10, 2021 | — | — | — | -$175.00 | -$125.00 | +28.57% | — | — |
| Q3 2021 Sep 24, 2021 | — | — | — | -$170.00 | -$205.00 | -20.59% | — | — |
| Q2 2021 May 13, 2021 | — | — | — | -$120.00 | -$205.00 | -70.83% | — | — |